How US could fall behind China in AI development

The United States is still viewed as the world’s leader in researching and developing AI solutions—but could that reputation be at stake?

According to a new report from Yahoo Finance, two professors from the MIT Sloan School of Management spoke at the World Economic Forum in Davos, Switzerland, about how the United States could fall behind in AI and other advanced technologies.

The professors, Erik Brynjolfsson and Andrew McAfee, noted that the United States is still a leader in these areas right now—but other countries, especially China, are pushing forward in an impressive manner. Massive investments in these technologies and continued government support appear to be the two biggest factors helping these countries advance.

“The key is to not lose the position that we have,” McAfee said, as quoted by Yahoo Finance. “When the world’s most intelligent, ambitious, and tenacious people in this field want to come to America to build their lives and careers and we put this Kafka-esque barriers in their place ... if our president is on board, let’s get these people here.”

Click the link below for the full report:

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup